New PET technologies – embracing progress and pushing the limits

Aide, Nicolas; Lasnon, Charline; Kesner, Adam; Levin, Craig S.; Buvat, Irène; Iagaru, Andrei; Hermann, Ken; Badawi, Ramsey D.; Cherry, Simon R.; Bradley, Kevin M.; McGowan, Daniel R.

doi:10.1007/s00259-021-05390-4

Cited by 39 publications

(35 citation statements)

References 82 publications

(108 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this context, positron emission tomography (PET) is gaining a central role for several reasons, emerging as a predominant imaging modality. Technological advancement has allowed the development of new hybrid tomographs, in which PET is associated with the state of the art of computed tomography (CT- PET/CT) or magnetic resonance (MR- PET/MR) technologies, which are able to provide increasingly detailed information both on the functional (PET imaging) and on the morphological side (CT and MR imaging) [ 122 , 123 ].…”

Section: In Vivo Biomarkers For Immunotherapy: Molecular Imagingmentioning

confidence: 99%

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images

Liberini

Mariniello

Righi

et al. 2021

Cancers

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer-related death, and it is usually diagnosed in advanced stages (stage III or IV). Recently, the availability of targeted strategies and of immunotherapy with checkpoint inhibitors (ICI) has favorably changed patient prognosis. Treatment outcome is closely related to tumor biology and interaction with the tumor immune microenvironment (TME). While the response in molecular targeted therapies relies on the presence of specific genetic alterations in tumor cells, accurate ICI biomarkers of response are lacking, and clinical outcome likely depends on multiple factors that are both host and tumor-related. This paper is an overview of the ongoing research on predictive factors both from in vitro/ex vivo analysis (ranging from conventional pathology to molecular biology) and in vivo analysis, where molecular imaging is showing an exponential growth and use due to technological advancements and to the new bioinformatics approaches applied to image analyses that allow the recovery of specific features in specific tumor subclones.

show abstract

Section: In Vivo Biomarkers For Immunotherapy: Molecular Imagingmentioning

confidence: 99%

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images

Liberini

Mariniello

Righi

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…In this context, positron emission tomography (PET) is gaining a central role for several reasons, emerging as a predominant imaging modality. Technological advancement has allowed the development of new hybrid tomographs, in which PET is associated with the state of the art of computed tomography (CT-PET/CT) or magnetic resonance (MR-PET/MR) technologies, able to provide increasingly detailed information both on the functional (PET imaging) and on the morphological side (CT and MR imaging) [110,111].…”

Section: In-vivo Biomarkers For Immunotherapy: Molecular Imagingmentioning

confidence: 99%

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to in-Vivo Images

Liberini

Mariniello

Righi

et al. 2021

Preprint

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer-related death and it is usually diagnosed in advanced stages (stage III or IV). Recently, the availability of targeted strategies and of immunotherapy with checkpoint inhibitors (ICI) has favorably changed patient prognosis. Treatment outcome is closely related to tumor biology and interaction with the host immune microenvironment (TME). Whether for targeted therapies the response relies on the presence of specific genetic alterations in tumor cells, for ICI accurate biomarkers of response are lacking and clinical outcome likely depends on multiple factors, host and tumor-related. This paper is an overview of the ongoing research on predictive factors both from in-vitro/ex-vivo analysis (ranging from conventional pathology to molecular biology) and in-vivo analysis, where molecular imaging is showing an exponential growth and use due to the technological advancement and to the new bioinformatics approaches applied to image analyses that allow specific features recovery in specific tumor subclones.

show abstract

“…PET-CT imaging involves CT acquisition—low dose CT for attenuation correction or diagnostic CT including contrast media—which is performed within few breath holds. The PET acquisition is performed with advanced PET-scanner technology (i.e., time-of-flight, continuous bed motion, silicon-photomultiplier) [ 2 ], and after application of 18 F-fluorodeoxyglucose ( 18 F-FDG)—still the workhorse of PET imaging—or a variety of radiotracers reflecting different molecular or pathophysiologic parameters. A main strength of PET-CT is the performance of whole-body imaging in a reasonable time-frame, with the total acquisition time of a scan (from the base of the skull to mid-thigh), nowadays, not exceeding 30 min.…”

Section: Technical Background Hybrid Petmentioning

confidence: 99%

Adapting Imaging Protocols for PET-CT and PET-MRI for Immunotherapy Monitoring

Beuthien‐Baumann

Sachpekidis

Gnirs

et al. 2021

Cancers

View full text Add to dashboard Cite

Hybrid imaging with positron emission tomography (PET) in combination with computer tomography (CT) is a well-established diagnostic tool in oncological staging and restaging. The combination of PET with magnetic resonance imaging (MRI) as a clinical scanner was introduced approximately 10 years ago. Although MRI provides superb soft tissue contrast and functional information without the radiation exposure of CT, PET-MRI is not as widely introduced in oncologic imaging as PET-CT. One reason for this hesitancy lies in the relatively long acquisition times for a PET-MRI scan, if the full diagnostic potential of MRI is exploited. In this review, we discuss the possible advantages of combined imaging protocols of PET-CT and PET-MRI, within the context of staging and restaging of patients under immunotherapy, in order to achieve “multi-hybrid imaging” in one single patient visit.

show abstract

New PET technologies – embracing progress and pushing the limits

Cited by 39 publications

References 82 publications

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to in-Vivo Images

Adapting Imaging Protocols for PET-CT and PET-MRI for Immunotherapy Monitoring

Contact Info

Product

Resources

About